日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Optimizing aesthetics in gender-affirming vaginoplasty and vulvoplasty: a narrative review and discussion based on over 600 cases of transfeminine vulvar construction

优化性别肯定阴道成形术和外阴成形术的美学效果:基于600多例跨性别女性外阴重建病例的叙述性综述和讨论

Peters, Blair R; Carboy, Jourdan A; Richards, Holden; Dy, Geolani W; Dugi, Daniel 3rd

Urinary symptoms after genital gender-affirming penile construction, urethral lengthening and vaginectomy

阴茎重建、尿道延长和阴道切除术后的泌尿系统症状

Fascelli, Michele; Sajadi, Kamran P; Dugi, Daniel D; Dy, Geolani W

Remote Stewardship for Medically Underserved Nurseries: A Stepped-Wedge, Cluster Randomized Study

针对医疗服务不足的托儿所的远程管理:一项阶梯楔形整群随机研究

Cantey, Joseph B; Correa, Cynthia C; Dugi, Daniel D; Huff, Erin; Olaya, Jorge E; Farner, Rachael

Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design

地加瑞克与亮丙瑞林治疗晚期前列腺癌的心血管安全性:PRONOUNCE试验研究设计

Melloni, Chiara; Slovin, Susan F; Blemings, Allan; Goodman, Shaun G; Evans, Christopher P; Nilsson, Jan; Bhatt, Deepak L; Zubovskiy, Konstantin; Olesen, Tine K; Dugi, Klaus; Clarke, Noel W; Higano, Celestia S; Roe, Matthew T

Phalloplasty: techniques and outcomes

阴茎成形术:技术和结果

Heston, Aaron L; Esmonde, Nick O; Dugi, Daniel D 3rd; Berli, Jens Urs

Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin

TCF7L2基因变异对二肽基肽酶-4抑制剂利格列汀治疗反应的影响

Zimdahl, Heike; Ittrich, Carina; Graefe-Mody, Ulrike; Boehm, Bernhard O; Mark, Michael; Woerle, Hans-Juergen; Dugi, Klaus A

Urotrauma: AUA guideline

泌尿系统创伤:美国泌尿外科协会指南

Morey, Allen F; Brandes, Steve; Dugi, Daniel David 3rd; Armstrong, John H; Breyer, Benjamin N; Broghammer, Joshua A; Erickson, Bradley A; Holzbeierlein, Jeff; Hudak, Steven J; Pruitt, Jeffrey H; Reston, James T; Santucci, Richard A; Smith, Thomas G 3rd; Wessells, Hunter

The epidemiological Boehringer Ingelheim Employee study--part I: impact of overweight and obesity on cardiometabolic risk

勃林格殷格翰员工流行病学研究——第一部分:超重和肥胖对心血管代谢风险的影响

Kempf, Kerstin; Martin, Stephan; Döhring, Carmen; Dugi, Klaus; Wolfram von Wolmar, Carolin; Haastert, Burkhard; Schneider, Michael

Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus

恩格列净多次递增剂量治疗2型糖尿病患者的安全性、耐受性、药代动力学和药效学

Heise, Tim; Seman, Leo; Macha, Sreeraj; Jones, Peter; Marquart, Alexandra; Pinnetti, Sabine; Woerle, Hans J; Dugi, Klaus

Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus

利格列汀可提高肠促胰岛素水平,降低胰高血糖素水平,并改善2型糖尿病患者的血糖控制。

Rauch, Thomas; Graefe-Mody, Ulrike; Deacon, Carolyn F; Ring, Arne; Holst, Jens J; Woerle, Hans-Juergen; Dugi, Klaus A; Heise, Tim